Antitumor activity of the marine natural product dibromophakellstatin in vitro

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 2, 2007, Pages 346-349

  Zöllinger, Michael ^a   Kelter, Gerhard ^b   Fiebig, Heinz Herbert ^b   Lindel, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antitumor activity; Dibromophakellstatin; Enantiomer; Marine natural products; Pyrrole imidazole alkaloids

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; DIBROMOPHAKELLSTATIN; IMIDAZOLE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL CULTURE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHIRAL CHROMATOGRAPHY; CONTROLLED STUDY; DEBROMINATION; DRUG MECHANISM; ENANTIOMER; FEMALE; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; OVARY CANCER; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMIDAZOLES; PYRROLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846047483     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.046     Document Type: Article

References (16)

1. Al-Mourabit A., and Potier P. Eur. J. Org. Chem. (2001) 237
2. Hoffmann H., and Lindel T. Synthesis (2003) 1753
3. Jacquot D.E.N., and Lindel T. Curr. Org. Chem. 9 (2005) 1551
4. Pettit G.R., McNulty J., Herald D.L., Doubek D.L., Chapuis J.C., Schmidt J.M., Tackett L.P., and Boyd M.R. J. Nat. Prod. 60 (1997) 180
5. Jacquot D.E.N., Hoffmann H., Polborn K., and Lindel T. Tetrahedron Lett. 43 (2002) 3699
6. Jacquot D.E.N., Zöllinger M., and Lindel T. Angew. Chem., Int. Ed. 44 (2005) 2295
7. CCDC-618899 (9), CCDC-618900 (10), CCDC-614042 (13), CCDC-614039 (14), CCDC-614045 (15), and CCDC-614046 (16) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: +44 1223 336 033; or deposit@ccdc.cam.ac.uk).
8. 2O-Cl 350.8535, found 350.8535.
9. Dengler W.A., Schulte J., Berger D.P., Mertelsmann R., and Fiebig H.-H. Anti-Cancer Drugs 6 (1995) 522
10. Roth T., Burger A.M., Dengler W., Willmann H., and Fiebig H.-H. In: Fiebig H.-H., and Burger A.M. (Eds). Relevance of Tumor Models for Anticancer Drug Development (1999), Karger, Basel 145-156
11. Fiebig H.-H., Dengler W.A., and Roth T. In: Fiebig H.-H., and Burger A.M. (Eds). Relevance of Tumor Models for Anticancer Drug Development (1999), Karger, Basel 29-50
12. Fiebig H.-H., Berger D.P., Dengler W.A., Wallbrecher E., and Winterhalter B.R. In: Fiebig H.-H., and Burger A.M. (Eds). Immunodeficient Mice in Oncology (1992), Karger, Basel 321-351
13. Kelter G., Metz T., Maier A., Fehr J., Korrat A., Bausch N., and Fiebig H.-H. Clin. Cancer Res. 11 (2005) 8987s (abstract A94)
14. Alberts D.S., Fanta P.T., Running K.L., Adair Jr. L.P., Garcia D.J., Liu-Stevens R., and Salmon S.E. Cancer Chemother. Pharmacol. 39 (1997) 493
15. Hoffmann T.K., Leenen K., Hafner D., Balz V., Gerharz C.D., Grund A., Balló H., Hauser U., and Bier H. Anti-Cancer Drugs 13 (2002) 93
16. Segraves N.L., Robinson S.J., Garcia D., Said S.A., Fu X., Schmitz F.J., Pietraszkiewicz H., Valeriote F.A., and Crews P. J. Nat. Prod. 67 (2004) 783